RxDoctor Payments Data

Nabeel Akhter

Vascular & Interventional Radiology · Baltimore, MDNPI 1487847075

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (45.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Boston Scientific at 42.5% of the total. Reporting peaked in 2022 at $3,261 and has fallen 68.2% since, to $1,038 in 2025.

$14,342in general payments, 2019–2025

Across 77 payments — averaging $186.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$6K
  • Penumbra, Inc.$4K
  • Canon Medical Systems USA, Inc.$3K
  • Biocompatibles, Inc.$981
  • Angiodynamics, Inc.$398
  • Intera Oncology, Inc$228
  • plus $168 from 5 others

What the payments were for

  • Consulting fees$2,50017%
  • Travel & lodging$6,57646%
  • Food & beverage$5,26737%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,342 in reported general payments places this provider in the 80th percentile of 75 vascular & interventional radiology providers in Maryland.

See all vascular & interventional radiology providers in Maryland

Medicare billing

Part B allowed, 2024
$147,145
Medicare patients
1,187
Services billed
2,341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Omeprazole27$381
Ondansetron Hcl25$99
Hydromorphone Hcl15$46

Paid to pharmacies, not to this prescriber.

Other vascular & interventional radiology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →